Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. (ZYME) is a clinical-stage biotechnology leader developing innovative bispecific antibodies and antibody-drug conjugates for oncology and autoimmune diseases. This page serves as the definitive source for ZYME news, providing investors and industry professionals with timely updates on therapeutic advancements and corporate developments.
Access consolidated updates including clinical trial milestones, regulatory filings, strategic partnerships, and financial results. Our curated collection features official press releases and verified news about ZYME's proprietary platforms like Azymetric™ and Albucore™, alongside collaborations with global biopharma leaders.
Key content categories include progress reports on novel cancer therapies, licensing agreements, scientific presentations, and pipeline expansion announcements. All materials maintain strict factual accuracy while avoiding speculative analysis to support informed decision-making.
Bookmark this page for efficient tracking of ZYME's advancements in multifunctional biotherapeutics. Check regularly for updates on their pioneering work in antibody engineering and targeted cancer treatment solutions.
Zymeworks (NASDAQ: ZYME) presented six posters featuring new preclinical data at the 2025 AACR Annual Meeting, showcasing progress in their antibody-drug conjugate and T cell engager platforms. Key highlights include:
- ZW209: A novel T cell engager demonstrating durable activity in small cell lung cancer, with IND submission expected in 1H-2026
- ZW171: A mesothelin-targeting T cell engager in Phase 1 clinical study showing strong anti-tumor activity in lung, ovarian, and pancreatic cancers
- ZW327: A first-in-class Ly6E-targeting antibody-drug conjugate displaying robust anti-tumor activity across various cancer types
The company also presented findings on their biparatopic antibody-drug conjugates targeting PTK7 and developments in 3D tumor models for improved ADC screening.
Zymeworks Inc. (Nasdaq: ZYME) has appointed Dr. Sabeen Mekan as Senior Vice President of Clinical Development to lead the clinical development strategy for its oncology portfolio and global regulatory affairs. Dr. Mekan brings 18 years of experience in hematology and oncology across academic research, clinical practice, and biopharmaceutical industry development.
The company also announced organizational changes with Dr. Jeff Smith continuing as Executive Vice President & Chief Medical Officer, focusing on autoimmune and inflammatory disease R&D portfolio, while Barbara Schaeffler has been promoted to Senior Vice President of Clinical Development Operations.
Dr. Mekan's previous roles include Executive Director at Gilead Sciences, Senior Medical Director at Daiichi Sankyo, and Medical Director at Bristol-Myers Squibb. She will support Zymeworks' development of next-generation antibody-drug conjugates and multispecific antibody therapeutics for gynecological, thoracic, and digestive system cancers.
Zymeworks (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after market close on May 8, 2025, followed by a conference call and webcast at 4:30 pm Eastern Time on the same day. Management will provide both financial updates and a corporate overview during the call.
Zymeworks (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, has announced its participation in two major upcoming investor conferences.
The company will be present at the Needham 24th Annual Virtual Healthcare Conference, where management will conduct one-on-one meetings and deliver a presentation on April 8 at 9:30 am ET. Additionally, Zymeworks will participate in the Stifel 2025 Virtual Targeted Oncology Forum on April 9 at 12:30 pm ET, featuring one-on-one meetings and a fireside chat.
Zymeworks (NASDAQ: ZYME) announced the acceptance of six abstracts for poster presentation at the upcoming AACR Annual Meeting in April 2025. The presentations highlight two key developments:
1. ZW209: A novel trispecific T cell engager targeting DLL3-expressing tumors, showing potent preclinical efficacy and favorable safety profile. The company plans IND submission in 1H-2026.
2. ZW327: A new antibody-drug conjugate (ADC) candidate targeting Ly6E, demonstrating anti-tumor activity and favorable pharmacokinetics in various cancers.
Additional presentations include data on ZW171, a mesothelin-targeting T cell engager in Phase 1 trials, showing promising activity in multiple cancer models, and research on biparatopic antibody-drug conjugates targeting PTK7 in various tumor types.
Zymeworks (NASDAQ: ZYME) reported key developments and financial results for Q4 and full-year 2024. The company achieved significant milestones, including the FDA accelerated approval of Ziihera® for HER2-positive biliary tract cancer and initiation of first-in-human studies for two pipeline products: ZW191 and ZW171.
Financial highlights include $324.2 million in cash resources as of December 31, 2024, with projected runway into 2H-2027. Revenue was $76.3 million in 2024, including a $25 million milestone payment from Jazz for Ziihera's approval. The company reported a net loss of $122.7 million for 2024.
Key pipeline updates include: accelerated IND submission timeline to mid-2025 for ZW251 (targeting GPC3), ongoing Phase 1 trials for ZW191 in FR⍺-expressing tumors and ZW171 in advanced cancers, and paused development of ZW220. Ziihera® achieved initial sales of $1.1 million in December 2024 following FDA approval.
Zymeworks (Nasdaq: ZYME) has announced the achievement of a significant $14 million cash research milestone from its collaboration with GSK. The milestone payment is associated with a clinical achievement in their partnership. Zymeworks, a clinical-stage biotechnology company, focuses on developing novel, multifunctional biotherapeutics aimed at improving treatment standards for challenging conditions including cancer, inflammation, and autoimmune diseases.
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing multifunctional biotherapeutics for diseases including cancer, inflammation, and autoimmune disease, has announced its participation in four upcoming investor conferences in March 2025.
The company's management will attend the TD Cowen 45th Annual Health Care Conference in Boston on March 4, presenting at 10:30 am ET. They will also present at the Leerink Global Healthcare Conference in Miami on March 10 at 8:00 am ET.
Additionally, Zymeworks will participate in one-on-one meetings at the Barclays 27th Annual Global Healthcare Conference on March 11 and the Jefferies Biotech on the Beach Summit on March 12, both in Miami, FL.
Zymeworks Inc. (Nasdaq: ZYME) has appointed Oleg Nodelman to its board of directors, effective February 17, 2025. Nodelman, the Founder and Managing Director of EcoR1 Capital, , represents the largest current stockholder of Zymeworks and brings over two decades of investment management experience to the role.
This appointment marks the seventh new director added in the past two years as part of the company's board renewal process. Nodelman, who holds a Bachelor of Science in Foreign Service from Georgetown University, currently serves as a director at Galapagos NV and AnaptysBio. His expertise in business development, capital deployment, and deep connections in the biotech sector position him as a strategic addition to support Zymeworks' mission of developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases.
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, has scheduled its fourth quarter and full year 2024 financial results announcement for March 5, 2025, after market close.
The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day, where management will discuss the financial results and provide a corporate update. Investors can access the webcast live and replay through Zymeworks' investor relations website.
